Drug Patent Watch

OCTOBER 22, 2024

The biopharmaceutical industry has witnessed a significant shift towards outsourcing, with contract development and manufacturing organizations (CDMOs) playing a crucial role in bringing innovative medicines to market. Here are some key tips to ensure better results… Source

Pharmaceutical Companies 90

Pharmaceutical Companies Drug Development Pharmaceuticals Marketing 90

Drug Patent Watch

OCTOBER 28, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. Here are the top 10 CDMO services you might not have known you needed… Source

Pharmaceutical Companies 83

Pharmaceutical Companies Pharmaceuticals Drug Development Drugs 83

Advarra

AUGUST 10, 2023

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

Drug Patent Watch

AUGUST 26, 2024

The pharmaceutical industry has increasingly relied on Contract Development and Manufacturing Organizations (CDMOs) to support the development and commercialization of drugs. CDMOs offer a range of services, from drug development to manufacturing, allowing pharmaceutical companies to focus on their core competencies.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drug Development Drugs 59

DrugBank

AUGUST 9, 2024

  The average cost of bringing a new drug to market is about $2.6 billion, with a development timeline spanning 10 to 15 years. Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. reported in 2021. trillion by 2028.

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

DrugBank

APRIL 12, 2024

Over the past decade, the drug discovery landscape has been revolutionized by the adoption of artificial intelligence (AI) and machine learning (ML), witnessing early adopters leapfrog into pioneering technologies aimed at streamlining the drug development process and curtailing associated costs.

Drugs 83

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 83

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Clinical Development Pharmaceutical Companies Drug Development 98

DrugBank

JUNE 27, 2024

Drug repurposing is an approach that, while not new, has become popular in the last decade.   One of the most exciting prospects of drug repurposing is its potential to tackle "undruggable" targets—proteins or molecules that traditional drugs can't easily bind to.

Drugs 72

Drugs Pharma Companies Clinical Trials Computational Chemistry 72

DrugBank

OCTOBER 4, 2024

For example, Gilead Sciences' acquisition of Immunomedics in 2020 included Trodelvy, an antibody-drug conjugate approved for treating triple-negative breast cancer. The IP surrounding Trodelvy , including patents covering the drug's composition, manufacturing process, and clinical use, was a significant valuation component.

Pharmaceuticals 81

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 81

DrugBank

NOVEMBER 4, 2024

While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.  

Pharmaceutical Companies 72

Pharmaceutical Companies Government Pharmaceuticals DNA 72

Drug Target Review

OCTOBER 14, 2024

who shared his thoughts on the challenges faced by biotech companies in drug discovery, highlighting the critical role of data and technology in overcoming inefficiencies in the pharmaceutical industry. Reflecting on the past 30 years, Wilkie noted the significant shift in how data has been used within drug discovery.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market.

Pharmaceutical Companies 81

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 81

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

DS in Pharmatics

FEBRUARY 24, 2023

Drug development is an immensely complex undertaking consisting of many different, interconnected processes. Specialist regulatory affairs consultants offer services to companies operating across this challenging industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Regulations Drug Development Pharmaceuticals 52

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? The pipeline currently includes five drug candidates, all of which have the potential to revolutionise the treatment of PD.

Disease 52

Disease Drugs Treatment Drug Development 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. Let’s dive in to uncover the role of digital health and data in driving faster drug development through improved diversity.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Pharma Data

MAY 5, 2022

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells.

Disease 52

Disease Clinical Trials Drug Development Pharmaceutical Companies 52

Drug Target Review

NOVEMBER 27, 2024

Introduction Biomarkers are becoming increasingly essential in drug development and clinical practice, driving the need for more precise validation methods. 2 The biomarker development pipeline involves multiple stages, including discovery, analytical validation, clinical validation and regulatory qualification. only about 0.1

Drug Development 52

Drug Development Regulations Laboratories FDA 52

H1 Blog

JULY 30, 2024

This effort seeks to provide the pharmaceutical industry with more accurate representation of patient populations, thereby enhancing the safety and efficacy for prescription drugs and medical devices. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

Drug Target Review

SEPTEMBER 19, 2023

puts an end to the previous mandate that all drugs need to be tested on animals prior to human clinical trials. This major shift to the orthodox tradition of using animal experiments in drug testing dates back the Aristotle’s time and cemented 80 years ago with initial federal mandate of drug safety regulation of 1938.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

FDA Law Blog: Drug Discovery

MARCH 6, 2024

Charles assists clients across a range of FDA-related regulatory matters by providing timely strategic advice on new drug and biologic development and helping them tackle complex regulatory issues.

FDA 59

FDA Compliance Pharmaceuticals Pharmaceutical Companies 59

PPD

JULY 20, 2023

In clinical research, the role of drug packaging systems cannot be overlooked. Industry guidelines require biopharmaceutical and biotechnology companies to test their pharmaceutical packaging systems, as the systems often experience prolonged and intimate contact with drug products, drug substances and intermediates.

Packaging 52

Packaging Laboratories Pharmaceutical Companies Compliance 52

thought leadership

JUNE 19, 2023

Across biotech startups and global pharmaceutical companies alike, Veeva Vault continues to expand market share. With 1,300+ customers, Veeva Systems is one of the largest providers of cloud solutions for the life sciences industry.

Pharmaceutical Companies 40

Pharmaceutical Companies Drug Development Science Pharmaceuticals 40

PPD

JUNE 20, 2024

To accelerate clinical research timelines, pharmaceutical developers need to tap into solutions that demonstrably streamline drug development from start to finish. The finish line: Powering your success It’s time for pharmaceutical developers to make clinical research timelines work for them, not against them.

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

Drug Target Review

AUGUST 15, 2023

Prochownik, delved into the dual role of the Myc gene in both cancer development and ageing. The findings highlight the gene’s complex functions, opening up new avenues for cancer therapy and raising important considerations for future drug development.

Research 98

Research Pharmaceutical Companies Drug Development Therapies 98

Conversations in Drug Development Trends

DECEMBER 7, 2023

At Worldwide, we understand that every program is different, which means every drug development path forward will be unique. Rather than settling for an “off-the-shelf” approach, you deserve a team that actively seeks customized solutions tailored to your specific study.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Drug Target Review

JANUARY 5, 2024

Scientists from the Centre for Genomic Regulation and the Wellcome Sanger Institute have found the allosteric control sites in the KRAS protein, the highly sought after targets for drug development. To control a protein, molecular signals work by opening a lock, the active site, with a key, a chemical compound or drug.

Regulations 98

Regulations Pharmaceutical Companies DNA Drug Development 98

Advarra

APRIL 4, 2024

Continuity of Experience Imagine a pharmaceutical company is embarking on a series of clinical trials for a particular therapeutic area, such as oncology or neurology. This continuity of experience enables the DSMB to provide the pharmaceutical company with more nuanced and informed recommendations throughout the entire program.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials FDA 52

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. What evidence is there that we can reverse aging with drugs?

Science 145

Science Disease FDA Approval Clinical Trials 145

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Not failed drugs, but failed studies. As soon as drug developers can begin to develop conviction, momentum increases.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Crown Bioscience

MAY 4, 2021

Unfortunately, children have limited access to novel therapies, and new drugs for adults are often only tested in children many years following approval. Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Codon

APRIL 9, 2024

sweet wormwood), from which artemisinin, the antimalarial drug, was first isolated. Artemisinin-based drugs work by causing Plasmodium proteins to unfold and by inhibiting new proteins from folding properly, which eventually destroys the parasite. ’s Good Manufacturing Practice standards for drug production.

Drugs 131

Drugs Science Research Doctors 131

H1 Blog

SEPTEMBER 14, 2023

As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future for the industry and to make trials more effective, efficient and accessible. million data points.”

Clinical Trials 59

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 59